Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat +/- Bortezomib in Advanced CTCL
NCT01386398Phase 3Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Modality
- Small Molecules, Modified Peptides
01
Overview
Phase 3, randomised, open-label trial of bortezomib in cutaneous T-cell lymphoma (CTCL) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-Free Survival. Status: withdrawn.
02
Drugs
bortezomib
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT01386398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01386398.